StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.72−0.24 (-3.02%)

Close on Nov 19, 2026Market cap $1.27BP/E –Yield –

Novavax shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Novavax's shares outstanding was 165M at Jun 30, 2026. For fiscal 2025 it was 173M, up 13.7% from the year before. Over ten years it grew 158.3% a year on average. The highest annual figure on record is 173M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 2025173M+13.7%
FY2024Dec 31, 2024152M+51.0%
FY2023Dec 31, 2023101M+28.9%
FY2022Dec 31, 202278M+5.1%
FY2021Dec 31, 202174M+29.3%
FY2020Dec 31, 202058M+138.8%
FY2019Dec 31, 201924M+30.4%
FY2018Dec 31, 201818M+26.3%
FY2017Dec 31, 201715M+8.1%
FY2016Dec 31, 201614M+103164.9%
FY2015Dec 31, 20150M+16.1%
FY2014Dec 31, 20140M-99.9%
FY2013Dec 31, 20138M+128702.0%
FY2012Dec 31, 20120M+15.9%
FY2011Dec 31, 20110M+8.5%
FY2010Dec 31, 20100M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026165M-7.1%
Q1 FY2026Mar 31, 2026163M-8.1%
Q4 FY2025Dec 31, 2025188M+17.2%
Q3 FY2025Sep 30, 2025162M+1.4%
Q2 FY2025Jun 30, 2025177M+6.8%
Q1 FY2025Mar 31, 2025178M+27.0%
Q4 FY2024Dec 31, 2024160M+29.3%
Q3 FY2024Sep 30, 2024160M+54.7%
Q2 FY2024Jun 30, 2024166M+59.4%
Q1 FY2024Mar 31, 2024140M+62.4%
Q4 FY2023Dec 31, 2023124M+55.2%
Q3 FY2023Sep 30, 2023103M+32.1%
Q2 FY2023Jun 30, 2023104M+33.2%
Q1 FY2023Mar 31, 202386M+6.7%
Q4 FY2022Dec 31, 202280M+5.5%
Q3 FY2022Sep 30, 202278M+4.7%
Q2 FY2022Jun 30, 202278M+5.4%
Q1 FY2022Mar 31, 202281M+10.5%
Q4 FY2021Dec 31, 202176M+15.0%
Q3 FY2021Sep 30, 202175M+21.4%
Q2 FY2021Jun 30, 202174M+26.4%
Q1 FY2021Mar 31, 202173M+64.4%
Q4 FY2020Dec 31, 202066M+134.0%
Q3 FY2020Sep 30, 202062M+153.0%
Q2 FY2020Jun 30, 202059M+149.7%
Q1 FY2020Mar 31, 202044M+117.3%
Q4 FY2019Dec 31, 201928M+46.7%
Q3 FY2019Sep 30, 201924M+27.3%
Q2 FY2019Jun 30, 201923M+24.9%
Q1 FY2019Mar 31, 201920M+21.3%
Q4 FY2018Dec 31, 201819M+21.2%
Q3 FY2018Sep 30, 201819M+29.0%
Q2 FY2018Jun 30, 201819M+32.6%
Q1 FY2018Mar 31, 201817M+122801.7%
Q4 FY2017Dec 31, 201716M+116604.4%
Q3 FY2017Sep 30, 201715M–
Q2 FY2017Jun 30, 201714M–
Q1 FY2017Mar 31, 20170M–
Q3 FY2016Sep 30, 20160M–

More Novavax figures

See a number that looks wrong?